2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…2015 American Transplant Congress
Association of De Novo Antibody-Mediated Rejection and Increased Hospital Costs Following Kidney Transplant in Immunologically Low-Risk Patients
While antibody-mediated rejection (AMR) is likely the primary cause of kidney transplant (KTx) failure, and its treatment can be considered expensive, incremental center costs for…2015 American Transplant Congress
Impact of Pre-Transplant Panel Reactive Antibody Levels On Renal Graft Survival in Patients With Negative Cross-Match and No Donor Specific Antibody
Purposes: This study was conducted to investigate the impact of pre-transplant PRA level on rejection and graft survival after kidney transplantation in patients with negative…2015 American Transplant Congress
First Clinical Data With an Improved C1q-Luminex® Assay
1Nephrology, Charite Hospital, Berlin, Germany; 2HLA Laboratory, Charite Hospital, Berlin, Germany.
Background: Chronic allograft dysfunction remains the main obstacle for long-term success of kidney transplantation. Immunological factors, in particular HLA-antibodies, contribute to long-term allograft loss. Identification…2015 American Transplant Congress
Cyclophosphamide as a Salvage Therapy for Combined Intravenous Immunoglobulins and Plasmapheresis Refractory Antibody-Mediated Rejection
Acute antibody-mediated rejection (AMR) poses a significant risk to graft survival. Current or standard treatment (ST) of AMR currently consists of plasmapheresis (PP), intravenous immunoglobulin…2015 American Transplant Congress
DSA Detected by ELISA-PRA Is Associated With High Risk for Development of AMR in Stable Kidney Transplant Recipients
Background: Donor specific anti-HLA antibodies (DSA) are a major cause of antibody mediated rejection (AMR) and allograft loss, determining how to monitor patients for DSA…2015 American Transplant Congress
Eculizumab in the Treatment of Early Severe Acute Antibody Mediated Rejection Following HLA-Compatible Kidney Transplantation-Case Series
Severe early acute antibody-mediated rejection (AMR) is associated with poor allograft outcomes. Eculizumab is a humanized mouse monoclonal antibody against complement factor C5 that has…2015 American Transplant Congress
Novel Flow Cytometry Method for Detecting Complement-Fixing Blood Group IgG Antibody in ABO-Incompatible Renal Transplantation
【Background】We experienced a hyperacute rejection (HAR) in ABO-incompatible renal transplantation (ABO-I RTx) on POD 0. We hypothesized that complement-fixing IgG anti-A/B blood group antibody (anti-A/B…2015 American Transplant Congress
Effect of Antibody Mediated Rejection on Long-Term Renal Allograft Function
Transplant Institute, Tulane University, New Orleans, LA.
Historically we had poor understanding of chronic rejection attributing it to hypertension and non-compliance. However in the last decade we have begun to understand the…2015 American Transplant Congress
Longitudinal eGFR Modelling to Understand Rates of eGFR Decline in Renal Transplantation in the United Kingdom
Background: The rate of decline in eGFR (slope) has been independently associated with a higher risk of cardiovascular events and all cause mortality in kidney…
American Transplant Congress abstracts